Any current/future new fundraising through debt or equity?

No explicit mention of any new fundraising through debt or equity at present or in the near future. The company has recently completed a QIP (Qualified Institutional Placement) raising around Rs. 500 crore, used mainly for debt repayment (~Rs. 250 crore) and CAPEX. Current cash and cash equivalents stand at Rs. 279 crore. No mention of plans for further QIP or debt raising during FY25 or FY26. CAPEX guidance for FY25 is Rs. 250 crore and FY26 is Rs. 40 crore, expected to be funded through internal accruals and existing resources. Management highlighted cautious investment approach, especially

Any current/future capex/capital investment/strategic investment?

FY25 CAPEX for AMI Organics is around ₹250 crore, including: - ₹70 crore for Unit 2 Ankleshwar site (expected completion Q3 FY25) - ₹100 crore for electrolyte additive project (capacity 2000 MT for VC and FEC, completion expected by Q1 FY26) - ₹60 crore for captive solar power plant (completion expected by end Q3 FY25) - ₹30 crore for regular maintenance CAPEX FY26 CAPEX is expected to be around ₹40 crore primarily for maintenance. Strategic investments include: - Expansion of Ankleshwar unit capacity to 442 KL in three blocks, fully operational over three years. - Electrolyte ad

Future growth expectations in sales/revenue/volumes?

AMI Organics targets a 30% revenue growth for FY25, revised upward from 25%, driven by strong order book and forecast. The company expects a consistent ~25% CAGR growth in the medium term based on a robust product pipeline and existing CDMO contracts. CDMO business to scale up materially from Q3 FY25 onwards, providing sizable additional revenue. Ankleshwar unit at full utilization is expected to generate around ₹900 crore revenue, with 310 crore CAPEX invested. The ramp-up for the Fermion contract and CDMO projects will continue through FY25, with full capacity utilization expected by

Future growth expectations in earnings/operating earnings/profits/EPS?

AMI Organics targets a revenue CAGR of approximately 25% annually, supported by a strong product pipeline extending to 2045. FY25 growth guidance is revised to 30%, considered conservative by management. Margins are expected to improve steadily, with a goal to exceed 25%-30% EBITDA margin within the next three years (versus current ~20%). CDMO segment expected to show significant growth from next quarter onwards, contributing to margin expansion. The Fermion contract and other CDMO projects in advanced stages will contribute to sizable revenue growth in coming years. CAPEX investments (Rs. 250

Current/ Expected Orderbook/ Pending Orders?

The management mentioned that the 30% top-line growth guidance for FY25 is based on forecast and orders currently on hand, indicating a healthy order book supporting this growth. CDMO project ramp-up is still underway with full effect expected beyond Q2 FY25. For the Fermion contract, sales are ramping up gradually with full utilization expected by FY26, covering multiple regulated markets. New contracts with originator clients in Europe are near completion, expected to result in supplies starting Q4 FY25 or Q1 FY26. Validation batches for electrolyte additives have been supplied; commercial o

Acutaas Chemicals LtdQ2 FY25Pharmaceuticals & Biotechnology

Acutaas Chemicals Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,196P/E: 69.4Market Cap: ₹26.8K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

Yes

Order

Yes

Capex

Yes

4 of 5 growth signals are positive — a strong management growth story.

Full analysis

Revenue guidance

Category 2

AMI Organics targets a 30% revenue growth for FY25, revised upward from 25%, driven by strong order book and forecast.
The company expects a consistent ~25% CAGR growth in the medium term based on a robust product pipeline and existing CDMO contracts.
CDMO business to scale up materially from Q3 FY25 onwards, providing sizable additional revenue.
Ankleshwar unit at full utilization is expected to generate around ₹900 crore revenue, with 310 crore CAPEX invested.
The ramp-up for the Fermion contract and CDMO projects will continue through FY25, with full capacity utilization expected by FY26.
Specialty Chemicals (excluding Baba Fine Chem) is growing over 25%, and pharma intermediates grew 53% Y-o-Y in Q2 FY25.
New geographic expansions (e.g., Korea, Japan) and product launches support growth beyond FY25.
EBITDA margins expected to improve on operational leverage and stabilized pricing through FY25-FY26.

Margin guidance

Category 1

AMI Organics targets a revenue CAGR of approximately 25% annually, supported by a strong product pipeline extending to 2045.
FY25 growth guidance is revised to 30%, considered conservative by management.
Margins are expected to improve steadily, with a goal to exceed 25%-30% EBITDA margin within the next three years (versus current ~20%).
CDMO segment expected to show significant growth from next quarter onwards, contributing to margin expansion.
The Fermion contract and other CDMO projects in advanced stages will contribute to sizable revenue growth in coming years.
CAPEX investments (Rs. 250 crore in FY25) and new Ankleshwar unit ramp-up will enable scaling and higher profitability.
Long-term visibility driven by ongoing contracts with originators and generic players.
Deferral in EV battery investments may delay related growth, but overall demand recovery anticipated from FY26 onwards.

See what Acutaas Chemicals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

No explicit mention of any new fundraising through debt or equity at present or in the near future.
The company has recently completed a QIP (Qualified Institutional Placement) raising around Rs. 500 crore, used mainly for debt repayment (~Rs. 250 crore) and CAPEX.
Current cash and cash equivalents stand at Rs. 279 crore.
No mention of plans for further QIP or debt raising during FY25 or FY26.
CAPEX guidance for FY25 is Rs. 250 crore and FY26 is Rs. 40 crore, expected to be funded through internal accruals and existing resources.
Management highlighted cautious investment approach, especially regarding the EV-related JV, waiting for clear visibility before committing funds.

Order book

Yes

The management mentioned that the 30% top-line growth guidance for FY25 is based on forecast and orders currently on hand, indicating a healthy order book supporting this growth.
CDMO project ramp-up is still underway with full effect expected beyond Q2 FY25.
For the Fermion contract, sales are ramping up gradually with full utilization expected by FY26, covering multiple regulated markets.
New contracts with originator clients in Europe are near completion, expected to result in supplies starting Q4 FY25 or Q1 FY26.
Validation batches for electrolyte additives have been supplied; commercial orders depend on customer approvals and may start as early as Q3 or Q4 FY25.
Overall, a strong product pipeline with multiple phase II and III drug intermediates in the pipeline supports growth visibility.
Ankleshwar unit expected to be fully operational by Q4 FY25, with 3x revenue potential over CAPEX indicating robust future order traction.

See what Acutaas Chemicals Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

FY25 CAPEX for AMI Organics is around ₹250 crore, including:
- ₹70 crore for Unit 2 Ankleshwar site (expected completion Q3 FY25)
- ₹100 crore for electrolyte additive project (capacity 2000 MT for VC and FEC, completion expected by Q1 FY26)
- ₹60 crore for captive solar power plant (completion expected by end Q3 FY25)
- ₹30 crore for regular maintenance CAPEX
FY26 CAPEX is expected to be around ₹40 crore primarily for maintenance.
Strategic investments include:
- Expansion of Ankleshwar unit capacity to 442 KL in three blocks, fully operational over three years.
- Electrolyte additive capacity build-up following long-term contracts.
- Careful evaluation and cautious investment in EV-related projects due to deferrals in the EV market.
- Potential joint venture with Enchem under discussion, status quo currently.
₹88 crore from QIP reserved for general corporate purposes and future opportunities.

Track Acutaas Chemicals Ltd — get its next earnings analysis in your feed

How does Acutaas Chemicals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAcutaas Chemicals Ltd

Rev 2Mar 1

See where Acutaas Chemicals Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Acutaas Chemicals Ltd rank in Pharmaceuticals & Biotechnology?

Compare Acutaas Chemicals Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Acutaas Chemicals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →